Study summary
On frexalimab, few people relapsed over three years
8%had any relapse over three years on the higher dose
What was tested
Frexalimab, an antibody that blocks CD40L, a signal between immune cells, in relapsing MS. The extension had no comparison group.
What they found
- Only 8% of people on the 1,200 mg dose had a relapse recorded over the extended follow-up.
- New MRI lesions fell sharply in the original 12-week trial.
- Phase 3 results in relapsing and progressive MS are expected from 2027.
What it means
A new mechanism that does not deplete B cells. Phase 3 will show how it compares with today's strongest drugs.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.